NeuroDerm launches initial public offering of 4,500,000 shares

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced the launch of its initial public offering of 4,500,000 ordinary shares pursuant to a registration statement on Form F-1 filed with the U.S. Securities and Exchange Commission (SEC). NeuroDerm has applied to list its ordinary shares on the Nasdaq Global Market under the ticker symbol "NDRM."

Jefferies LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering. Oppenheimer & Co. Inc. and Roth Capital Partners, LLC are acting as co-managers for the proposed offering.

SOURCE NeuroDerm Ltd